Stockscreener 앱 받기
28.78
6.04%
1.64
시장 영업 전:
28.96
0.18
+0.63%
Nektar Therapeutics 주식(NKTR)의 최신 뉴스
How to monitor Nektar Therapeutics with trend dashboards2025 Earnings Surprises & Verified Entry Point Signals - Newser
Candlestick signals on Nektar Therapeutics stock todayMarket Trend Summary & Reliable Volume Spike Trade Alerts - Newser
Applying big data sentiment scoring on Nektar TherapeuticsJuly 2025 Patterns & Consistent Profit Alerts - Newser
Using data models to predict Nektar Therapeutics stock movementJuly 2025 Institutional & Verified Swing Trading Watchlist - Newser
Is Nektar Therapeutics stock ready for a breakoutPortfolio Performance Summary & Growth Focused Investment Plans - Newser
Sentiment analysis tools applied to Nektar TherapeuticsJuly 2025 Macro Moves & High Accuracy Investment Signals - Newser
Using Ichimoku Cloud for Nektar Therapeutics technicalsJuly 2025 Closing Moves & Real-Time Buy Zone Alerts - Newser
Measuring Nektar Therapeutics’s beta against major indices2025 Retail Activity & Safe Investment Capital Preservation Plans - Newser
Nektar Therapeutics Crosses 200 Day MA — Signal or Noise2025 Buyback Activity & AI Based Trade Execution Alerts - beatles.ru
Published on: 2025-08-25 21:46:25 - Newser
Sector ETF Data Correlates with Strength in Nektar TherapeuticsJuly 2025 Intraday Action & Low Risk Entry Point Tips - newsyoung.net
How sentiment analysis helps forecast Nektar TherapeuticsBreakout Watch & Comprehensive Market Scan Reports - Newser
Is Nektar Therapeutics a candidate for recovery playPrice Action & Precise Trade Entry Recommendations - Newser
Can momentum traders help lift Nektar TherapeuticsVolume Spike & Free Risk Controlled Daily Trade Plans - Newser
Using Python tools to backtest Nektar Therapeutics strategies2025 Big Picture & Advanced Swing Trade Entry Plans - Newser
Will Nektar Therapeutics benefit from macro trendsJuly 2025 PreEarnings & Long-Term Investment Growth Plans - Newser
Signal strength of Nektar Therapeutics stock in tech scannersEarnings Risk Report & Fast Gain Swing Alerts - Newser
Nektar Therapeutics stock outlook for YEAR2025 Market Outlook & Real-Time Buy Zone Alerts - Newser
Long term hold vs stop loss in Nektar TherapeuticsDollar Strength & Daily Profit Focused Screening - Newser
Trend analysis for Nektar Therapeutics this weekRecession Risk & AI Based Trade Execution Alerts - Newser
What MACD signals say about Nektar TherapeuticsChart Signals & Free Accurate Trade Setup Notifications - Newser
Key resistance and support levels for Nektar TherapeuticsQuarterly Portfolio Report & Expert Curated Trade Setups - Newser
Nektar Therapeutics: Fairly Valued, High-Quality Biotech With Multiple Near-Term Catalysts - Seeking Alpha
Can Nektar Therapeutics expand into new marketsJuly 2025 Highlights & High Yield Stock Recommendations - 더경남뉴스
Nektar Therapeutics Executives Sell Shares - TradingView
ORIC® Pharmaceuticals Expands Leadership Team with the Appointment of Kevin Brodbeck as Chief Technical Officer - The Manila Times
Nektar Q2 Loss Narrower Than Expected, Revenues Fall Y/Y - MSN
Institutions Profited After Nektar Therapeutics' (NASDAQ:NKTR) Market Cap Rose US$80m Last Week but Retail Investors Profited the Most - 富途牛牛
Top 5 Articles of the Week: August 10-15 - Dermatology Times
What makes Nektar Therapeutics stock price move sharplyDividend Hike & Growth Oriented Trading Recommendations - Newser
Nektar upgraded at Oppenheimer on upcoming mid-stage trial readout - MSN
Nektar Therapeutics Sees Relief Buying After Extended DropEarnings Overview Summary & Fast Exit Strategy with Risk Control - sundaytimes.kr
Nektar gets FDA fast track status for alopecia areata drug - MSN
Why Nektar Therapeutics Stock Popped 6% on Friday - MSN
Nektar Therapeutics shares fall 1.61% premarket as cancer research funding faces uncertainty. - AInvest
Cancer Treatment Stocks Surge as $866B Market Attracts Private Investment - MarketScreener
Nektar Therapeutics’ Earnings Call Highlights Growth Potential - TipRanks
Quant Tools Rank Nektar Therapeutics as High Risk High Reward2025 Stock Rankings & AI Powered Market Entry Strategies - metal.it
Institutional investors are Nektar Therapeutics' (NASDAQ:NKTR) biggest bettors and were rewarded after last week's US$59m market cap gain - simplywall.st
Leading vs lagging indicators on Nektar Therapeutics performanceFree Weekly Watchlist of High Movers - Newser
Nektar Therapeutics Rebounds From Oversold Zone — Now WhatLong Term Wealth Forecast - beatles.ru
Nektar Therapeutics (NASDAQ:NKTR) Q2 2025 Earnings Call Transcript - Insider Monkey
How Nektar's Rezpegaldesleukin Could Redefine Treatment for Autoimmune Disorders - Dermatology Times
Analysts Are Bullish on Top Healthcare Stocks: Arcellx Inc (ACLX), Nektar Therapeutics (NKTR) - The Globe and Mail
Nektar Therapeutics Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
0.95%
0.90%
자본화:
|
볼륨(24시간):